BiotechTube

PTI-125, 100 mg tablets

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease

Trial Timeline

Mar 7, 2019 → May 8, 2019

NCT ID
NCT03748706

About PTI-125, 100 mg tablets

PTI-125, 100 mg tablets is a phase 2 stage product being developed by Cassava Sciences for Alzheimer Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03748706. Target conditions include Alzheimer Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03748706Phase 2Completed

Competing Products

20 competing products in Alzheimer Disease

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
44
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
40
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
Zagotenemab + PlaceboEli LillyPhase 2
52
Donanemab + Placebo + LY3202626Eli LillyPhase 2
52
Donanemab + PlaceboEli LillyPhase 3
77
GSK4527226AlectorPhase 2
44
AL002 + PlaceboAlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
donanemabEli LillyPhase 2
52
ATH-1017LeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2
44
NDX-1017 + PlaceboLeonaBioPhase 1
25
simufilamCassava SciencesPhase 2
44
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
25

Other Products from Cassava Sciences

Simufilam + PlaceboPhase 3
69
SimufilamPhase 3
69
Simufilam + PlaceboPhase 3
69
Placebo oral tablet + Simufilam 100 mg tablet + Simufilam 50 mg oral tabletPhase 2
44
Simufilam 100 mg oral tablet + PlaceboPhase 2
44